Approaches for treating neuropsychiatric symptoms in Parkinson's disease: a narrative review

被引:0
作者
Rodriguez-Antiguedad, Jon [1 ,2 ,3 ,4 ]
Olmedo-Saura, Gonzalo [1 ,2 ,3 ,4 ]
Pagonabarraga, Javier [1 ,2 ,3 ,4 ]
Martinez-Horta, Saul [1 ,2 ,3 ,4 ]
Kulisevsky, Jaime [1 ,2 ,3 ,4 ]
机构
[1] Hosp Santa Creu i St Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
[2] Univ Autonoma Barcelona UAB, Med Dept, Barcelona, Spain
[3] Inst Invest Biomed St Pau IIB St Pau, Barcelona, Spain
[4] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
关键词
neuropsychiatric symptoms; non-motor symptoms; Parkinson's disease; treatment; MILD COGNITIVE IMPAIRMENT; IMPULSE CONTROL DISORDERS; QUALITY-OF-LIFE; CLINICAL DIAGNOSTIC-CRITERIA; DEEP BRAIN-STIMULATION; CORTICAL LEWY BODIES; NONMOTOR SYMPTOMS; DOUBLE-BLIND; SUBTHALAMIC STIMULATION; DEPRESSIVE SYMPTOMS;
D O I
10.1177/17562864251336903
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuropsychiatric symptoms in Parkinson's disease (PD) are highly prevalent and profoundly disabling, often emerging even before the onset of motor symptoms. As the disease progresses, these symptoms usually become increasingly impairing and are now recognized as having the greatest impact on quality of life not only for patients but also for caregivers. In recent years, there have been significant advances in the diagnosis and management of neuropsychiatric symptoms. However, there are still substantial gaps in therapeutic approaches and algorithms, with limited pharmacological and nonpharmacological treatment options currently available. One of the main reasons for this is the complex molecular and neural bases of these symptoms, which involve both dopaminergic and nondopaminergic neurotransmission systems and extend far beyond the nigrostriatal pathway. As a result, the drugs currently recommended for treating neuropsychiatric symptoms in PD are few and supported by limited evidence. In this context, the experience of the treating neurologist remains critical in selecting the most appropriate individualized therapy. The aim of this paper is to review the available therapeutic options and provide an overview of current research efforts, particularly those focusing on pharmacological treatments.
引用
收藏
页数:20
相关论文
共 192 条
[31]   Depression and Anxiety Following Deep Brain Stimulation in Parkinson's Disease: Systematic Review and Meta-Analysis [J].
Couto, Maria Ines ;
Monteiro, Ana ;
Oliveira, Ana ;
Lunet, Nuno ;
Massano, Joao .
ACTA MEDICA PORTUGUESA, 2014, 27 (03) :372-382
[32]   Psychological treatment of generalized anxiety disorder: A meta-analysis [J].
Cuijpers, Pim ;
Sijbrandij, Marit ;
Koole, Sander ;
Huibers, Marcus ;
Berking, Matthias ;
Andersson, Gerhard .
CLINICAL PSYCHOLOGY REVIEW, 2014, 34 (02) :130-140
[33]   Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial [J].
Cummings, Jeffrey ;
Isaacson, Stuart ;
Mills, Roger ;
Williams, Hilde ;
Chi-Burris, Kathy ;
Corbett, Anne ;
Dhall, Rohit ;
Ballard, Clive .
LANCET, 2014, 383 (9916) :533-540
[34]   Apathy following subthalamic stimulation in Parkinson disease:: A dopamine responsive symptom [J].
Czernecki, Virginie ;
Schuepbach, Michael ;
Yaici, Sadek ;
Levy, Richard ;
Bardinet, Eric ;
Yelnik, Jerome ;
Dubois, Bruno ;
Agid, Yves .
MOVEMENT DISORDERS, 2008, 23 (07) :964-969
[35]   Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease A Meta-analysis [J].
d'Angremont, Emile ;
Begemann, Marieke J. H. ;
van Laar, Teus ;
Sommer, Iris E. C. .
JAMA NEUROLOGY, 2023, 80 (08) :813-823
[36]   Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts [J].
Dafsari, Haidar Salimi ;
Petry-Schmelzer, Jan Niklas ;
Ray-Chaudhuri, K. ;
Ashkan, Keyoumars ;
Weis, Luca ;
Dembek, Till A. ;
Samuel, Michael ;
Rizos, Alexandra ;
Silverdale, Monty ;
Barbe, Michael T. ;
Fink, Gereon R. ;
Evans, Julian ;
Martinez-Martin, Pablo ;
Antonini, Angelo ;
Visser-Vandewalle, Veerle ;
Timmermann, Lars .
BRAIN STIMULATION, 2018, 11 (04) :904-912
[37]   Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study [J].
Dashtipour, Khashayar ;
Chen, Jack J. ;
Kani, Camellia ;
Bahjri, Khaled ;
Ghamsary, Mark .
PHARMACOTHERAPY, 2015, 35 (07) :681-686
[38]   Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials [J].
Dauwan, Meenakshi ;
Begemann, Marieke J. H. ;
Slot, Margot I. E. ;
Lee, Edwin H. M. ;
Scheltens, Philip ;
Sommer, Iris E. C. .
JOURNAL OF NEUROLOGY, 2021, 268 (04) :1222-1246
[39]   Initiation of pharmacological therapy in Parkinson's disease: when, why, and how [J].
de Bie, Rob M. A. ;
Clarke, Carl E. ;
Espay, Alberto J. ;
Fox, Susan H. ;
Lang, Anthony E. .
LANCET NEUROLOGY, 2020, 19 (05) :452-461
[40]   Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease [J].
Deane, Katherine H. O. ;
Flaherty, Helen ;
Daley, David J. ;
Pascoe, Roland ;
Penhale, Bridget ;
Clarke, Carl E. ;
Sackley, Catherine ;
Storey, Stacey .
BMJ OPEN, 2014, 4 (12)